EQUILLA CHERRY: Open Payments
NPI 1689029480 · LAKELAND, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$960 in 60 payments from 8 companies in 2025. Trend: 2023 $1,333 · 2024 $1,451 · 2025 $960
Food & beverage: $960
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $255 |
| E.R. Squibb & Sons, L.L.C. | 9 | $175 |
| Teva Pharmaceuticals USA, Inc. | 17 | $173 |
| Luye Pharma (USA) Ltd. | 6 | $128 |
| Vanda Pharmaceuticals Inc. | 3 | $65 |
| Janssen Pharmaceuticals, Inc | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
Products named: ARISTADA, COBENFY, ERZOFRI EXTENDED-RELEASE, AUSTEDO XR, LYBALVI, UZEDY, FANAPT, INVEGA.
Industry payments across FL — which companies pay providers there.
